成都路橋(002628.SZ):李勤及其一致行動人恆康中迪累計減持3437.7萬股
格隆匯12月18日丨成都路橋(002628.SZ)公佈,公司於2019年12月18日收到公司持股5%以上股東李勤及其一致行動人成都恆康中迪投資中心(有限合夥)(“恆康中迪”)送達的《簡式權益變動報告書》。
根據《簡式權益變動報告書》披露,信息披露義務人李勤及其一致行動人恆康中迪於2018年9月27日至2019年12月17日通過集中競價及大宗交易方式共計減持公司股份3437.7萬股,減持公司股份總數累計達到公司總股本的5%。
截至2019年12月18日,信息披露義務人李勤及其一致行動人恆康中迪仍合計持有公司股份約7664.41萬股,佔公司總股本的10.06%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.